MenAfriVac meningococcal A conjugate vaccine
MenAfriVac, vacuna conjugada contra la meningitis A
- Date
- 2010 · confidence high
- Place
- Ouagadougou, Burkina Faso
- Credited to
- Meningitis Vaccine Project (WHO and PATH), Serum Institute of India and African ministries of health
- Field
- Life & health
What it is
A conjugate vaccine designed at the request of the countries of the African meningitis belt, at under $0.50 a dose. It almost eliminated meningitis A epidemics in the Sahel.
Manufactured in Pune (India) using conjugation technology from the US FDA; the campaign began in December 2010 in Burkina Faso, Mali and Niger.
What it led to
- the disappearance of meningococcal A epidemics
- a model for developing affordable vaccines
- multivalent conjugate vaccines for Africa (MenFive, 2023)